Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Rhamnogalacturonan II is a Toll-like receptor 4 agonist that inhibits tumor growth by activating dendritic cell-mediated CD8þ T cells
- Authors
- Park, Yeong-Min; Noh, Kyung Tae; Jeong, Young-ll; Jung, In Duk; Kang, Hyun Kyu; Cha, Gil Sun; Lee, Su Jung; Seo, Jong Keun; Kang, Dae Hwan; Hwang, Tae Ho; Lee, Eun Kyung; Kwon, Byungsul; Park, Yeong-Min
- Issue Date
- 2013
- Publisher
- 생화학분자생물학회
- Keywords
- adjuvant; dendritic cells; rhamnogalacturonan II; Toll-like receptor 4; tumor
- Citation
- Experimental and Molecular Medicine, v.45, no.2, pp 1 - 11
- Pages
- 11
- Journal Title
- Experimental and Molecular Medicine
- Volume
- 45
- Number
- 2
- Start Page
- 1
- End Page
- 11
- ISSN
- 1226-3613
2092-6413
- Abstract
- We evaluated the effectiveness of rhamnogalacturonan II (RG-II)-stimulated bone marrow-derived dendritic cells (BMDCs)vaccination on the induction of antitumor immunity in a mouse lymphoma model using EG7-lymphoma cells expressing ovalbumin (OVA). BMDCs treated with RG-II had an activated phenotype. RG-II induced interleukin (IL)-12, IL-1b, tumor necrosis factor-a (TNF-a) and interferon-c (IFN-c) production during dendritic cell (DC) maturation. BMDCs stimulated with RG-II facilitate the proliferation of CD8þ T cells. Using BMDCs from the mice deficient in Toll-like receptors (TLRs), we revealed that RG-II activity is dependent on TLR4. RG-II showed a preventive effect of immunization with OVA-pulsed BMDCs against EG7 lymphoma. These results suggested that RG-II expedites the DC-based immune response through the TLR4signaling pathway.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > College of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.